Skip to main content

Bachem builds its largest production building

Bachem Bubendorf
| News

Bachem builds its largest production building

11.11.2021

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of peptides and oligonucleotides will initially create up to 150 new skilled jobs with this. This will strengthen the position of Bubendorf, located in the Basel Area, as a center of excellence.

Bachem Bubendorf
Bachem is specializing in the manufacture of peptides and oligonucleotides (img: Bachem)

Bachem has started construction of the world’s most high-tech production building for peptides and oligonucleotides at its location in Bubendorf in the canton of Basel-Landschaft. The foundation stone was laid on Thursday. According to a press release, the building should expand the production capacities for these complex molecules by 2024 at the latest. These substances are used in medicinal products used to treat various diseases.

In a first phase, up to 150 positions, most of which will be highly skilled, are to be created there. The listed company has invested over 150 million Swiss francs and created 400 new jobs at its two sites in Bubendorf and Vionnaz (in the canton of Valais) over the past five years. The new production building will now strengthen the Bubendorf site’s position as a “leading center of excellence for the manufacture of complex pharmaceutical active ingredients” according to the press release. Additionally, it represents a clear commitment to Switzerland and Basel Area as a location.

Since global demand for these molecules is constantly increasing, Bachem is already looking for a third production site in Switzerland. The land reserves at the Bubendorf site will be exhausted in the medium term.

The company celebrated its 50th anniversary this year. CEO Thomas Meier is delighted that the foundation stone was laid on Swiss National Future Day, which is a day for young people to learn about working in a company. Meier adds: “Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations for the impact chemistry and the natural sciences can have.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.